Advertisement

Drug Safety

, Volume 42, Issue 2, pp 315–334 | Cite as

Safety and Tolerability of Adoptive Cell Therapy in Cancer

  • Benita Wolf
  • Stefan Zimmermann
  • Caroline Arber
  • Melita Irving
  • Lionel Trueb
  • George CoukosEmail author
Review Article

Abstract

Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection. In recent years, some ACTs have produced unprecedented breakthrough responses: TIL therapy has moved from melanoma to solid tumor applications, TCR-engineered cells are developed for hematologic and solid tumors, and CAR-engineered T cells have received Food and Drug Administration (FDA) approval for the treatment of patients with certain B-cell malignancies. Although results are encouraging, to date, only a small percentage of patients with advanced malignancies can benefit from ACT. Besides ACT availability and accessibility, treatment-related toxicities represent a major hurdle in the widespread implementation of this therapeutic modality. The large variety of observed toxicities is caused by the infused cell product or as side effects of accompanying medication and chemotherapy. Toxicities can occur immediately or can be delayed. In order to render those highly promising therapeutic approaches safe enough for a wider pool of patients outside of clinical trials, an international consensus for toxicity management needs to be established.

Notes

Compliance with Ethical Standards

Institutional Review Board approval was not required because this is a review of the literature.

Conflict of interest

The authors of this manuscript declare relationships with the following companies: Prof. George Coukos, Dr Lionel Trueb, Dr Stefan Zimmermann, Dr Benita Wolf, Dr Melita Irving and Prof. Carline Arber are co-investigators in Iovance and Kite Pharma sponsored clinical studies at CHUV, Lausanne. Prof. Caroline Arber receives royalties from Cell Medica. Prof. Carline Arber has one patent issued in the field of engineered T-cell therapies licensed to Cell Medica in 2016. Prof. Caroline Arber has two provisional patent applications filed in the field of engineered T-cell therapies. Prof. Caroline Arber received consulting fees from Kite/Gilead.

Funding

The authors state that this work has not received any funding.

References

  1. 1.
    Harris DT, Kranz DM. Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci. 2016;37(3):220–30.  https://doi.org/10.1016/j.tips.2015.11.004.Google Scholar
  2. 2.
    Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–8.  https://doi.org/10.1126/science.aaa4967.Google Scholar
  3. 3.
    Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T cells in human melanoma. Nat Med. 2015;21(1):81–5.  https://doi.org/10.1038/nm.3773.Google Scholar
  4. 4.
    Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–7.  https://doi.org/10.1158/1078-0432.CCR-11-0116.Google Scholar
  5. 5.
    Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res. 1991;51(7):1934–9.Google Scholar
  6. 6.
    Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphas Tumor Immunol. 1994;16(3):198–210.Google Scholar
  7. 7.
    Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res. 1995;1(5):501–7.Google Scholar
  8. 8.
    Fabbri M, Ridolfi R, Maltoni R, Ridolfi L, Riccobon A, Flamini E, et al. Tumor infiltrating lymphocytes and continuous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma. Tumori. 2000;86(1):46–52.Google Scholar
  9. 9.
    Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol. 1988;6(5):839–53.  https://doi.org/10.1200/JCO.1988.6.5.839.Google Scholar
  10. 10.
    Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126–9.  https://doi.org/10.1126/science.1129003.Google Scholar
  11. 11.
    Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2(7):512–9.  https://doi.org/10.1038/nri841.Google Scholar
  12. 12.
    Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720–4.Google Scholar
  13. 13.
    June CH, Levine BL. T cell engineering as therapy for cancer and HIV: our synthetic future. Philos Trans R Soc Lond B Biol Sci. 2015;370(1680):20140374.  https://doi.org/10.1098/rstb.2014.0374.Google Scholar
  14. 14.
    Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 2003;63(10):2470–6.Google Scholar
  15. 15.
    Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33.  https://doi.org/10.1056/NEJMoa1103849.Google Scholar
  16. 16.
    Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, et al. Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res. 2015;21(10):2268–77.  https://doi.org/10.1158/1078-0432.CCR-14-1559.Google Scholar
  17. 17.
    Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, et al. CD8 + T cell immunity against a tumor/self-antigen is augmented by CD4 + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174(5):2591–601.Google Scholar
  18. 18.
    Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26(2):111–7.  https://doi.org/10.1016/j.it.2004.12.003.Google Scholar
  19. 19.
    Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25(3):243–51.Google Scholar
  20. 20.
    Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, et al. Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? Nat Clin Pract Oncol. 2006;3(12):668–81.  https://doi.org/10.1038/ncponc0666.Google Scholar
  21. 21.
    June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73.  https://doi.org/10.1056/NEJMra1706169.Google Scholar
  22. 22.
    Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26(4):332–42.Google Scholar
  23. 23.
    Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86(15):1159–66.Google Scholar
  24. 24.
    Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, et al. CD8 + enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;16(24):6122–31.  https://doi.org/10.1158/1078-0432.CCR-10-1297.Google Scholar
  25. 25.
    Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, et al. Randomized selection design trial evaluating CD8 + -enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013;31(17):2152–9.  https://doi.org/10.1200/JCO.2012.46.6441.Google Scholar
  26. 26.
    Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346–57.  https://doi.org/10.1200/JCO.2005.00.240.Google Scholar
  27. 27.
    Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233–9.  https://doi.org/10.1200/JCO.2008.16.5449.Google Scholar
  28. 28.
    Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013;19(17):4792–800.  https://doi.org/10.1158/1078-0432.CCR-13-0380.Google Scholar
  29. 29.
    Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, et al. Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother. 2011;34(2):212–20.  https://doi.org/10.1097/CJI.0b013e318209c94c.Google Scholar
  30. 30.
    Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18(24):6758–70.  https://doi.org/10.1158/1078-0432.CCR-12-1177.Google Scholar
  31. 31.
    Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res. 2010;16(19):4892–8.  https://doi.org/10.1158/1078-0432.CCR-10-1507.Google Scholar
  32. 32.
    Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676–80.  https://doi.org/10.1056/nejm198812223192527.
  33. 33.
    Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–iv42.  https://doi.org/10.1093/annonc/mdx225.
  34. 34.
    Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;18(6):792–802.  https://doi.org/10.1016/S1470-2045(17)30251-6.Google Scholar
  35. 35.
    Deniger DC, Kwong ML, Pasetto A, Dudley ME, Wunderlich JR, Langhan MM, et al. A pilot trial of the combination of vemurafenib with adoptive cell therapy in patients with metastatic melanoma. Clin Cancer Res. 2017;23(2):351–62.  https://doi.org/10.1158/1078-0432.CCR-16-0906.Google Scholar
  36. 36.
    Li J, Chen QY, He J, Li ZL, Tang XF, Chen SP, et al. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology. 2015;4(2):e976507.  https://doi.org/10.4161/23723556.2014.976507.Google Scholar
  37. 37.
    Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210(4):474–84 (discussion 84–5).Google Scholar
  38. 38.
    Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543–50.  https://doi.org/10.1200/JCO.2014.58.9093.Google Scholar
  39. 39.
    Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4 + T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–5.  https://doi.org/10.1126/science.1251102.Google Scholar
  40. 40.
    Libert C, Dejager L. How steroids steer T cells. Cell Rep. 2014;7(4):938–9.  https://doi.org/10.1016/j.celrep.2014.04.041.Google Scholar
  41. 41.
    Olnes MJ, Kotliarov Y, Biancotto A, Cheung F, Chen J, Shi R, et al. Effects of systemically administered hydrocortisone on the human immunome. Sci Rep. 2016;6:23002.  https://doi.org/10.1038/srep23002.Google Scholar
  42. 42.
    Schwartzentruber DJ. Interleukin-2: Clinical applications—principles of administration and management of side effects. In: Rosenberg AZ, editor. Principles and Practice of the Biologic Therapy of Cancer. Philadelphia: Lippincott, Williams & Wilkins; 2000. p. 32–50.Google Scholar
  43. 43.
    Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, et al. High dose interleukin-2 (Aldesleukin)—expert consensus on best management practices-2014. J ImmunoTher Cancer. 2014;2:26.Google Scholar
  44. 44.
    Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–16.  https://doi.org/10.1200/JCO.1999.17.7.2105.Google Scholar
  45. 45.
    Schwartz RN, Stover L, Dutcher JP. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park). 2002;16(11 Suppl 13):11–20.Google Scholar
  46. 46.
    Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother. 2001;24(4):287–93.Google Scholar
  47. 47.
    Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphas Tumor Immunol. 1995;18(4):272–8.Google Scholar
  48. 48.
    Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8 + T cell responsiveness. J Biol Chem. 2012;287(27):23068–78.  https://doi.org/10.1074/jbc.M112.357673.Google Scholar
  49. 49.
    Kunert A, Obenaus M, Lamers CHJ, Blankenstein T, Debets R. T-cell receptors for clinical therapy: in vitro assessment of toxicity risk. Clin Cancer Res. 2017;23(20):6012–20.  https://doi.org/10.1158/1078-0432.ccr-17-1012.Google Scholar
  50. 50.
    Zoete V, Irving M, Ferber M, Cuendet MA, Michielin O. Structure-based, rational design of T cell receptors. Front Immunol. 2013;4:268.  https://doi.org/10.3389/fimmu.2013.00268.Google Scholar
  51. 51.
    Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005;23(3):349–54.  https://doi.org/10.1038/nbt1070.Google Scholar
  52. 52.
    Raman MC, Rizkallah PJ, Simmons R, Donnellan Z, Dukes J, Bossi G, et al. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. Sci Rep. 2016;6:18851.  https://doi.org/10.1038/srep18851.Google Scholar
  53. 53.
    van Loenen MM, de Boer R, Amir AL, Hagedoorn RS, Volbeda GL, Willemze R, et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci USA. 2010;107(24):10972–7.  https://doi.org/10.1073/pnas.1005802107.Google Scholar
  54. 54.
    Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010;16(5):565–70, 1p following 70.  https://doi.org/10.1038/nm.2128.
  55. 55.
    Spear TT, Foley KC, Garrett-Mayer E, Nishimura MI. TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence. J Leukoc Biol. 2018;103(5):973–83.  https://doi.org/10.1002/JLB.5A0817-314R.Google Scholar
  56. 56.
    Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014;20(9):2457–65.  https://doi.org/10.1158/1078-0432.CCR-13-3017.Google Scholar
  57. 57.
    Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535–46.  https://doi.org/10.1182/blood-2009-03-211714.Google Scholar
  58. 58.
    Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–71.  https://doi.org/10.1182/blood-2013-03-490565.Google Scholar
  59. 59.
    Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620–6.  https://doi.org/10.1038/mt.2010.272.Google Scholar
  60. 60.
    Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, et al. Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J Clin Oncol. 2017;35(29):3322–9.  https://doi.org/10.1200/JCO.2017.74.5463.Google Scholar
  61. 61.
    Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133–51.  https://doi.org/10.1097/CJI.0b013e3182829903.Google Scholar
  62. 62.
    Davis JL, Theoret MR, Zheng Z, Lamers CH, Rosenberg SA, Morgan RA. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin Cancer Res. 2010;16(23):5852–61.  https://doi.org/10.1158/1078-0432.CCR-10-1280.Google Scholar
  63. 63.
    Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914–21.  https://doi.org/10.1038/nm.3910.Google Scholar
  64. 64.
    Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017;130(18):1985–94.  https://doi.org/10.1182/blood-2017-06-791202.Google Scholar
  65. 65.
    Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–24.  https://doi.org/10.1200/JCO.2010.32.2537.Google Scholar
  66. 66.
    Yang JC. Toxicities associated with adoptive T-cell transfer for cancer. Cancer J. 2015;21(6):506–9.  https://doi.org/10.1097/PPO.0000000000000157.Google Scholar
  67. 67.
    Janeway CATP, Walport M, Shlomchik MJ. Immunobiology: the immune system in health and disease. Immunobiology, 5th edition. New York: Garland Science; 2001.Google Scholar
  68. 68.
    Debets R, Donnadieu E, Chouaib S, Coukos G. TCR-engineered T cells to treat tumors: seeing but not touching? Semin Immunol. 2016;28(1):10–21.  https://doi.org/10.1016/j.smim.2016.03.002.Google Scholar
  69. 69.
    Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra03.  https://doi.org/10.1126/scitranslmed.3006034.Google Scholar
  70. 70.
    Hurwitz AA, Cuss SM, Stagliano KE, Zhu Z. T cell avidity and tumor immunity: problems and solutions. Cancer Microenviron. 2014;7(1–2):1–9.  https://doi.org/10.1007/s12307-013-0143-1.Google Scholar
  71. 71.
    Heemskerk MH, de Paus RA, Lurvink EG, Koning F, Mulder A, Willemze R, et al. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci USA. 2001;98(12):6806–11.  https://doi.org/10.1073/pnas.111162298.Google Scholar
  72. 72.
    Obenaus M, Leitao C, Leisegang M, Chen X, Gavvovidis I, van der Bruggen P, et al. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nat Biotechnol. 2015;33(4):402–7.  https://doi.org/10.1038/nbt.3147.Google Scholar
  73. 73.
    Bijen HM, van der Steen DM, Hagedoorn RS, Wouters AK, Wooldridge L, Falkenburg JHF, et al. Preclinical strategies to identify off-target toxicity of high-affinity TCRs. Mol Ther. 2018;26(5):1206–14.  https://doi.org/10.1016/j.ymthe.2018.02.017.Google Scholar
  74. 74.
    Govers C, Sebestyen Z, Coccoris M, Willemsen RA, Debets R. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med. 2010;16(2):77–87.  https://doi.org/10.1016/j.molmed.2009.12.004.Google Scholar
  75. 75.
    Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H, et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009;69(23):9003–11.  https://doi.org/10.1158/0008-5472.CAN-09-1450.Google Scholar
  76. 76.
    Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014;20(13):3401–10.  https://doi.org/10.1158/1078-0432.CCR-14-0433.Google Scholar
  77. 77.
    Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387–90.  https://doi.org/10.1126/science.aad1253.Google Scholar
  78. 78.
    Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24(5):743–50.  https://doi.org/10.1101/gr.165985.113.Google Scholar
  79. 79.
    van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31(32):e439–42.  https://doi.org/10.1200/JCO.2012.47.7521.Google Scholar
  80. 80.
    Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016;22(1):26–36.  https://doi.org/10.1038/nm.4015.Google Scholar
  81. 81.
    Gilham DE, Maher J. ‘Atypical’ CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors. Immunotherapy. 2017;9(9):723–33.  https://doi.org/10.2217/imt-2017-0045.Google Scholar
  82. 82.
    Cavalieri S, Cazzaniga S, Geuna M, Magnani Z, Bordignon C, Naldini L, et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood. 2003;102(2):497–505.  https://doi.org/10.1182/blood-2003-01-0297.Google Scholar
  83. 83.
    Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3(1):35–45.  https://doi.org/10.1038/nrc971.Google Scholar
  84. 84.
    Thomas S, Hart DP, Xue SA, Cesco-Gaspere M, Stauss HJ. T-cell receptor gene therapy for cancer: the progress to date and future objectives. Expert Opin Biol Ther. 2007;7(8):1207–18.  https://doi.org/10.1517/14712598.7.8.1207.Google Scholar
  85. 85.
    Zhou X, Cui Y, Huang X, Yu Z, Thomas AM, Ye Z, et al. Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther. 2003;14(11):1089–105.  https://doi.org/10.1089/104303403322124800.Google Scholar
  86. 86.
    Zhang Z, Qiu S, Zhang X, Chen W. Optimized DNA electroporation for primary human T cell engineering. BMC Biotechnol. 2018;18(1):4.  https://doi.org/10.1186/s12896-018-0419-0.Google Scholar
  87. 87.
    Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system. Cancer Res. 2008;68(8):2961–71.  https://doi.org/10.1158/0008-5472.CAN-07-5600.Google Scholar
  88. 88.
    Tipanee J, Chai YC, VandenDriessche T, Chuah MK. Preclinical and clinical advances in transposon-based gene therapy. Biosci Rep. 2017;37(6). doi: https://doi.org/10.1042/BSR20160614
  89. 89.
    Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002;3(11):999–1005.  https://doi.org/10.1038/ni1102-999.Google Scholar
  90. 90.
    Casucci M, Hawkins RE, Dotti G, Bondanza A. Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol Immunother. 2015;64(1):123–30.  https://doi.org/10.1007/s00262-014-1641-9.Google Scholar
  91. 91.
    Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.  https://doi.org/10.1126/scitranslmed.3005930.Google Scholar
  92. 92.
    Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.  https://doi.org/10.1126/scitranslmed.3008226.Google Scholar
  93. 93.
    Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.  https://doi.org/10.1126/scitranslmed.3002842.Google Scholar
  94. 94.
    Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–20.  https://doi.org/10.1182/blood-2011-10-384388.Google Scholar
  95. 95.
    Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9.  https://doi.org/10.1200/JCO.2014.56.2025.Google Scholar
  96. 96.
    Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–102.  https://doi.org/10.1182/blood-2010-04-281931.Google Scholar
  97. 97.
    Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.  https://doi.org/10.1126/scitranslmed.aaf8621.Google Scholar
  98. 98.
    Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119–22.  https://doi.org/10.1097/PPO.0000000000000035.Google Scholar
  99. 99.
    Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.  https://doi.org/10.1038/nrclinonc.2017.148.Google Scholar
  100. 100.
    Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6:4.  https://doi.org/10.1186/s40364-018-0116-0.Google Scholar
  101. 101.
    Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2018;22:22.  https://doi.org/10.1038/s41571-018-0075-2.Google Scholar
  102. 102.
    Teachey DT, Bishop MR, Maloney DG, Grupp SA. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ‘ALL’. Nat Rev Clin Oncol. 2018;15(4):218.  https://doi.org/10.1038/nrclinonc.2018.19.Google Scholar
  103. 103.
    Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.  https://doi.org/10.1056/NEJMoa1707447.Google Scholar
  104. 104.
    Schuster SJ, Bishop MR, Tam C, Waller EK, Borchmann P, Mcguirk J et al. Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)—an interim analysis. In: Oncology H, editor. 14th International conference on malignant lymphoma; 07.06.2017; Lugano (Switzerland): Hematological Oncology; 2017.Google Scholar
  105. 105.
    Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95.  https://doi.org/10.1182/blood-2014-05-552729.Google Scholar
  106. 106.
    Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18.  https://doi.org/10.1056/NEJMoa1215134.Google Scholar
  107. 107.
    Klaver Y, van Steenbergen SC, Sleijfer S, Debets R, Lamers CH. T cell maturation stage prior to and during GMP processing informs on CAR T cell expansion in patients. Front Immunol. 2016;7:648.  https://doi.org/10.3389/fimmu.2016.00648.Google Scholar
  108. 108.
    Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731–8.  https://doi.org/10.1038/s41591-018-0041-7.Google Scholar
  109. 109.
    Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–48.  https://doi.org/10.1038/s41591-018-0036-4.Google Scholar
  110. 110.
    Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28.  https://doi.org/10.1016/S0140-6736(14)61403-3.Google Scholar
  111. 111.
    Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–19.  https://doi.org/10.1158/2159-8290.CD-17-0698.Google Scholar
  112. 112.
    Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904–12.  https://doi.org/10.1038/mt.2013.17.Google Scholar
  113. 113.
    Irving M, de Silly RV, Scholten K, Dilek N, Coukos G. Engineering chimeric antigen receptor T-cells for racing in solid tumors: don’t forget the fuel. Front Immunol. 2017;8:267.  https://doi.org/10.3389/fimmu.2017.00267.Google Scholar
  114. 114.
    Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31(1):71–5.  https://doi.org/10.1038/nbt.2459.Google Scholar
  115. 115.
    Wiseman AC. Immunosuppressive Medications. Clin J Am Soc Nephrol. 2016;11(2):332–43.  https://doi.org/10.2215/CJN.08570814.Google Scholar
  116. 116.
    Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5:254.  https://doi.org/10.3389/fphar.2014.00254.Google Scholar
  117. 117.
    Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719–24.Google Scholar
  118. 118.
    Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009;10(5):489–500.  https://doi.org/10.1016/S1470-2045(09)70074-9.Google Scholar
  119. 119.
    Oliveira G, Greco R, Lupo-Stanghellini MT, Vago L, Bonini C. Use of TK-cells in haploidentical hematopoietic stem cell transplantation. Curr Opin Hematol. 2012;19(6):427–33.  https://doi.org/10.1097/MOH.0b013e32835822f5.Google Scholar
  120. 120.
    Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–83.  https://doi.org/10.1056/NEJMoa1106152.Google Scholar
  121. 121.
    Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24(6):1160–70.  https://doi.org/10.1038/leu.2010.75.Google Scholar
  122. 122.
    Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105(11):4247–54.  https://doi.org/10.1182/blood-2004-11-4564.Google Scholar
  123. 123.
    Introna M, Barbui AM, Bambacioni F, Casati C, Gaipa G, Borleri G, et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther. 2000;11(4):611–20.  https://doi.org/10.1089/10430340050015798.Google Scholar
  124. 124.
    Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood. 2014;124(8):1277–87.  https://doi.org/10.1182/blood-2014-01-545020.Google Scholar
  125. 125.
    Kieback E, Charo J, Sommermeyer D, Blankenstein T, Uckert W. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc Natl Acad Sci USA. 2008;105(2):623–8.  https://doi.org/10.1073/pnas.0710198105.Google Scholar
  126. 126.
    Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118(5):1255–63.  https://doi.org/10.1182/blood-2011-02-337360.Google Scholar
  127. 127.
    Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011.  https://doi.org/10.1038/mto.2016.11.Google Scholar
  128. 128.
    Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35.  https://doi.org/10.1182/blood-2009-08-239186.Google Scholar
  129. 129.
    Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4(132):132ra53.  https://doi.org/10.1126/scitranslmed.3003761.Google Scholar
  130. 130.
    Karpanen T, Olweus J. T-cell receptor gene therapy—ready to go viral? Mol Oncol. 2015;9(10):2019–42.  https://doi.org/10.1016/j.molonc.2015.10.006.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer ResearchUniversity of LausanneLausanneSwitzerland

Personalised recommendations